Assenagon Asset Management S.A. Sells 6,625,644 Shares of Pfizer Inc. $PFE

Assenagon Asset Management S.A. lessened its position in Pfizer Inc. (NYSE:PFE) by 76.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,063,459 shares of the biopharmaceutical company’s stock after selling 6,625,644 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Pfizer were worth $51,380,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. RF&L Wealth Management LLC bought a new stake in Pfizer during the fourth quarter valued at about $461,000. Diversified Trust Co. lifted its position in shares of Pfizer by 15.1% during the 4th quarter. Diversified Trust Co. now owns 153,067 shares of the biopharmaceutical company’s stock worth $3,811,000 after purchasing an additional 20,136 shares during the last quarter. Aull & Monroe Investment Management Corp lifted its position in shares of Pfizer by 1.8% during the 4th quarter. Aull & Monroe Investment Management Corp now owns 39,465 shares of the biopharmaceutical company’s stock worth $983,000 after purchasing an additional 700 shares during the last quarter. Post Resch Tallon Group Inc. boosted its stake in Pfizer by 85.4% during the 4th quarter. Post Resch Tallon Group Inc. now owns 30,526 shares of the biopharmaceutical company’s stock valued at $760,000 after purchasing an additional 14,065 shares during the period. Finally, 180 Wealth Advisors LLC boosted its stake in Pfizer by 3.0% during the 4th quarter. 180 Wealth Advisors LLC now owns 47,490 shares of the biopharmaceutical company’s stock valued at $1,182,000 after purchasing an additional 1,365 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on PFE shares. Barclays started coverage on Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target on the stock. Bank of America lowered their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a research report on Thursday, February 12th. Morgan Stanley set a $27.00 target price on shares of Pfizer and gave the company a “positive” rating in a research note on Tuesday, March 17th. Finally, UBS Group began coverage on shares of Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $28.19.

Pfizer Price Performance

Shares of PFE stock opened at $26.98 on Wednesday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The company has a market capitalization of $153.39 billion, a P/E ratio of 19.83 and a beta of 0.47. The stock has a 50 day moving average of $26.75 and a two-hundred day moving average of $25.64. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.63 earnings per share. As a group, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst upgrade/price-target bump: Guggenheim raised its Pfizer price target to $36 and holds a Buy rating, backing upside tied to key pipeline readouts and boosting sentiment among growth/pipeline-focused investors. Guggenheim price target report
• Positive Sentiment: Pipeline upside — prostate cancer and oncology momentum: Several analysts highlight potential high-value outcomes from an ongoing prostate-cancer trial and broader oncology progress, suggesting binary upside that could re-rate the stock if positive. Analyst bullish case on prostate cancer trial
• Neutral Sentiment: Management investor access — Q1 webcast scheduled for May 5: Pfizer invited the public to view a May 5 analyst call tied to its First Quarter 2026 Performance Report; that scheduled update creates a clear near-term catalyst for guidance or pipeline commentary. May 5 webcast invitation
• Neutral Sentiment: Management highlights oncology milestones: CFO Dave Denton discussed recent oncology progress on NYSE Live, reinforcing management’s message that non-COVID franchises and oncology are growth pillars. This supports a constructive narrative but is not immediately revenue-producing. CFO oncology interview
• Negative Sentiment: Lyme vaccine trial—strong efficacy but missed primary endpoint: Pfizer and partner Valneva reported >70% efficacy, yet the trial missed its pre-specified primary endpoint because fewer cases occurred than expected. That creates regulatory and execution uncertainty; Valneva’s shares plunged, underscoring market concern about read-across risk. Pfizer will pursue regulatory filings, but approval risk and timing remain uncertain. Lyme vaccine efficacy and trial miss

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.